Live tape
Top 8, mentions 7d12,577SPCX2,587 mentions▲ +0.08GOOGL2,050 mentions▲ +0.02META1,967 mentions▲ +0.04TSLA1,886 mentions▲ +0.05QQQ1,072 mentions▲ +0.05NFLX1,033 mentions▲ +0.03NVDA1,007 mentions▲ +0.07AMZN975 mentions▲ +0.06

Equity · Healthcare

MIRM

NASDAQ

Mirum Pharmaceuticals (MIRM)

$118.69 +1.09% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for MIRM to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $7.7B
52-week range $51 – $128
Avg volume 193.8K

as of Jul 17, 2026

Mirum Pharmaceuticals (MIRM) insider trades

SEC Form 4 · last 90 days · newest reported trade 14 Sep 2026

In the 90 days to 25 Oct 2026, Mirum Pharmaceuticals insiders reported 7 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 23 Jan 2026.

Open-market buys 0
Open-market sells 7
Net sold $10.78M
Non-trade filings 6
Date Insider Type Shares Value
14 Sep 2026 BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Sell 9,943 $978K
02 Sep 2026 Howe Jolanda SVP, GLOBAL CONTROLLER Sell 658 $66K
01 Sep 2026 Peetz Christopher CHIEF EXECUTIVE OFFICER Sell 30,000 $2.96M
18 Aug 2026 Howe Jolanda SVP, GLOBAL CONTROLLER Sell 40,000 $4.00M
11 Aug 2026 BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Sell 6,001 $600K
10 Aug 2026 Peetz Christopher CHIEF EXECUTIVE OFFICER Sell 20,000 $1.98M
03 Aug 2026 Howe Jolanda SVP, GLOBAL CONTROLLER Sell 1,840 $194K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
16 Oct 2026 Howe Jolanda SVP, GLOBAL CONTROLLER Option exercise 16,112 $310K
06 Oct 2026 Peetz Christopher CHIEF EXECUTIVE OFFICER Option exercise 12,197 $211K
11 Sep 2026 BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Option exercise 18,333
01 Sep 2026 Peetz Christopher CHIEF EXECUTIVE OFFICER Option exercise 30,000 $88K
18 Aug 2026 Howe Jolanda SVP, GLOBAL CONTROLLER Option exercise 40,000 $251K
10 Aug 2026 Peetz Christopher CHIEF EXECUTIVE OFFICER Option exercise 20,000 $59K

Mirum Pharmaceuticals (MIRM) reported financials

SEC EDGAR XBRL SEC EDGAR

Mirum Pharmaceuticals reported revenue of $521.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$23.4M.

Figure Reported Period
Revenue $521.3M 31 Dec 2025 fiscal year
Net income −$23.4M 31 Dec 2025 fiscal year
Diluted EPS −$0.47 31 Dec 2025 fiscal year
Total assets $1.0B 30 Jun 2026 at period end
Total equity −$10.4M 30 Jun 2026 at period end

Mirum Pharmaceuticals (MIRM) earnings

SEC EDGAR

Mirum Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.06; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.06 —
31 Mar 2026 Q1 2026 −$13.43 —
31 Dec 2025 FY 2025 −$0.47 —
30 Sep 2025 Q3 2025 $0.05 —
30 Jun 2025 Q2 2025 −$0.12 —
31 Mar 2025 Q1 2025 −$0.30 —
31 Dec 2024 FY 2024 −$1.85 —
30 Sep 2024 Q3 2024 −$0.30 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Mirum Pharmaceuticals (MIRM) institutional holders (13F)

SEC Form 13F SEC EDGAR

9 of the 45 institutional funds we track reported a Mirum Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $273.9M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Two Sigma Investments Held (±25%) −10.9% shares 690,318 $80.8M
Balyasny Asset Management Held (±25%) −9.3% shares 489,170 $57.3M
Baker Bros. Advisors Held (±25%) 445,975 $52.2M
Renaissance Technologies Held (±25%) −24.0% shares 442,185 $51.8M
Millennium Management Trimmed −73.9% shares 96,213 $11.3M
Fisher Asset Management Held (±25%) −11.4% shares 82,476 $9.7M
Man Group New position 37,183 $4.4M
AQR Capital Management Held (±25%) −9.9% shares 28,647 $3.4M
D. E. Shaw & Co. Trimmed −83.4% shares 27,879 $3.3M
Citadel Advisors Exited

Mirum Pharmaceuticals (MIRM) fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 26,924 shares of Mirum Pharmaceuticals failed to deliver (about $2.4M).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 26,924 $2.4M 0.041%
23 Sep 2026 8,767 $801K 0.014%
22 Sep 2026 44,759 $4.1M 0.069%
21 Sep 2026 32,778 $3.0M 0.050%
18 Sep 2026 37,524 $3.7M 0.058%
10 Sep 2026 27 $3K <0.001%
09 Sep 2026 17,137 $1.7M 0.026%

Mirum Pharmaceuticals (MIRM): frequently asked questions

From live data

Have Mirum Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 25 Oct 2026, Mirum Pharmaceuticals insiders reported 7 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 23 Jan 2026. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Mirum Pharmaceuticals?

9 of the 45 institutional funds we track reported a Mirum Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Mirum Pharmaceuticals had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Mirum Pharmaceuticals is dated 30 Sep 2026, when 26,924 shares failed to deliver.

When did Mirum Pharmaceuticals last report earnings?

Mirum Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.06; no next date is announced in SEC filings yet.

What exchange is Mirum Pharmaceuticals listed on?

Mirum Pharmaceuticals trades on NASDAQ under the ticker MIRM.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings